Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octacalcium phosphate + VEGFA plasmid DNA + autobone
- Development stage
- Unknown
- Lead developer
- Baikov Institute of Metallurgy and Materials Science
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Gene Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Local (intraosseous/implantation At Bone Defect Site)
01
Overview
A combination therapy composed of **octacalcium phosphate** (OCP), **vascular endothelial growth factor A (VEGFA) plasmid DNA**, and **autologous bone (autobone)**, designed as a gene-activated bone substitute for bone tissue regeneration. OCP acts as a biocompatible scaffold that delivers naked plasmid DNA encoding VEGFA, thereby promoting localized angiogenesis and osteoinduction. The plasmid DNA is released from the scaffold and taken up by local cells, where VEGFA expression is upregulated, stimulating neovascularization and supporting new bone formation. Autobone provides viable osteogenic cells and additional structural support. This approach leverages both the physical properties of the scaffold and the biological effects of gene therapy to enhance bone healing, particularly in large or critically sized bone defects. Preclinical evidence suggests enhanced vascularization and bone tissue regeneration compared to controls. Clinical trials have been initiated for device registration, indicating translational development for orthopedic or reconstructive applications[1][4].
- Other names
- octacalcium phosphate and VEGFA gene-activated autologous bone substituteOCP/pDNA-VEGFA + autobone
02
Targets
Beyond the preview
Go deeper on octacalcium phosphate + VEGFA plasmid DNA + autobone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octacalcium phosphate + VEGFA plasmid DNA + autobone.